Global Leiomyosarcoma Market Trends, Demand, Manufacturers and Opportunities 2017

Leiomyosarcoma Industry

Leiomyosarcoma - Pipeline Review, H2 2017

Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Leiomyosarcoma - Pipeline Review, H2 2017, provides an overview of the Leiomyosarcoma (Oncology) pipeline landscape.

Leiomyosarcoma is an aggressive soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal or soft tissue origin. Symptoms include a noticeable lump or swelling, pain, if it presses on nerves or muscles and a blockage in the stomach or intestines or gastrointestinal bleeding if the tumor is located in the abdomen or digestive tract. Predisposing factors include age, chemical exposure and radiation exposure. Treatment includes chemotherapy, radiation therapy and surgery.

Browse Full Table of Contents and Report Description @ https://www.reportsmonitor.com/leiomyosarcoma-pipeline-review-h2-2017/

Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Leiomyosarcoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Leiomyosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Leiomyosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Leiomyosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Leiomyosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Leiomyosarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Leiomyosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Leiomyosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Leiomyosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Leiomyosarcoma (Oncology)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Leiomyosarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Leiomyosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

For Requesting a Sample Copy of This Report, Please Visit @ https://goo.gl/sx98M8

Table of contents
Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 5
Global Markets Direct Report Coverage 5
Leiomyosarcoma – Overview 6
Leiomyosarcoma – Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 10
Products under Development by Companies 11
Products under Development by Universities/Institutes 12
Leiomyosarcoma – Therapeutics Assessment 13
Assessment by Target 13
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Leiomyosarcoma – Companies Involved in Therapeutics Development 21
Advenchen Laboratories LLC 21
BeiGene Ltd 21
Cell Medica Ltd 22
Karyopharm Therapeutics Inc 22
Merck & Co Inc 23
Merck KGaA 23
Millennium Pharmaceuticals Inc 24
Mirati Therapeutics Inc 24
Novartis AG 25
Ono Pharmaceutical Co Ltd 25
Pfizer Inc 26
Vicore Pharma AB 26
Yooyoung Pharm Co Ltd 27
Leiomyosarcoma – Drug Profiles 28
AL-3818 – Drug Profile 28
avelumab – Drug Profile 31
axitinib – Drug Profile 42
baltaleucel-T – Drug Profile 48
BGB-290 – Drug Profile 50
C-21 – Drug Profile 52
Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases – Drug Profile 55
everolimus – Drug Profile 56
mocetinostat – Drug Profile 68
nivolumab – Drug Profile 73
pembrolizumab – Drug Profile 122
sapanisertib – Drug Profile 183
selinexor – Drug Profile 187
YYB-101 – Drug Profile 209
Leiomyosarcoma – Dormant Projects 210
Leiomyosarcoma – Discontinued Products 211
Appendix 212
Methodology 212
Coverage 212
Secondary Research 212
Primary Research 212
Expert Panel Validation 212
Contact Us 212
Disclaimer 213

About Us
Reports Monitor (ReportsMonitor.com) is a platform to meet the market research and business intelligence requirements. Our aim is to change the dynamics of the Market Research industry by providing quality intelligence backed by data. Your requirement for market forecasting is fulfilled by our exclusive quantitative and analytics driven intelligence. We have a vast collection of reports, covering maximum industries worldwide. Our process is meticulously planned and executed in order to use maximum resources and explore the market for getting genuine insights. Decision makers can now rely on our distinct data gathering methods to get factual market forecasting and detailed analysis.

Contact Us
Jay Matthews
Direct: +1 513 549-5911
Email: sales@reportsmonitor.com
Website: www.reportsmonitor.com

This release was published on openPR.